Are all KRAS mutations created equal?

摘要

In this issue of The Lancet Oncology, Kenneth O'Byrne and colleagues report an analysis of potential biomarkers from a phase 3 trial of cisplatin and vinorelbine with and without eetuximab, an EGFR monoclonal antibody, in patients with advanced non-small-cell lung cancer (NSCLC). In 2009, KRAS codon 12 and 13 mutational status was recorded to be predictive of benefit of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in advanced colorectal cancer (CRC). The benefit of these agents was thought to be restricted to the subset of patients with KRAS wild-type tumours; consequently only patients with KRAS wild-type tumours receive these aqents.